Showing results (1201-1210 of 5,577) with videos related to

Sort By:
Pageof 558
Investigative Radiology|December 1, 1986
Observer variation in quantitative assessment of rheumatoid arthritis. Part I. Scoring erosions and joint space narrowingE P Nance, J J Kaye, L F Callahan, et al.
Investigative Radiology|October 28, 1997
Computed tomography characterization of renal cell tumors in correlation with histopathologyJ E Wildberger, G Adam, W Boeckmann, et al.
Investigative Radiology|October 28, 1997
Prospective evaluation of bone marrow signal changes on magnetic resonance tomography during high-dose chemotherapy and peripheral blood stem cell transplantation in patients with breast cancerC Altehoefer, J Laubenberger, W Lange, et al.
Investigative Radiology|October 28, 1997
Comparative cytotoxicity of low- and high-osmolar contrast media to human fibroblasts and rat mesangial cells in cultureM Potier, I Lagroye, B Lakhdar, et al.
Investigative Radiology|May 1, 1976
Considerations of 201T1 as a myocardial radionuclide imaging agent in manH R Schelbert, H Henning, P Rigo, et al.
Investigative Radiology|May 1, 1976
Metrizamide in experimental urography. V. Renal excretion mechanism of a non-ionic contrast medium in rabbit and catK Golman, C Scient
Investigative Radiology|December 24, 1997
Phase I clinical trials of MRX-115. A new ultrasound contrast agentT A Fritz, E C Unger, G Sutherland, et al.
Investigative Radiology|December 24, 1997
Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imagingD J Parmelee, R C Walovitch, H S Ouellet, et al.
Investigative Radiology|December 24, 1997
Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptorE C Wiener, S Konda, A Shadron, et al.
Investigative Radiology|December 24, 1997
Hemodynamic tolerance of intravascular contrast agents for magnetic resonance imagingF D Knollmann, R Sorge, A Mühler, et al.
Pageof 558